NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced that it is incorporating Horizon Discovery’s oncology cell lines into its offerings from Caliper Discovery Alliances and Services.
 
According to Hopkinton, Mass.-based Caliper, the deal provides CDAS with unique, genetically defined, and isogenic human cancer cell lines that will enable researchers to better identify and characterize personalized drugs targeted at specific subsets of patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.